1-11 of 11
Kim M. Linton
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma

Clinical Trials & Observations
Pietro R. Di Ciaccio, Mark N. Polizzotto, Kate Cwynarski, Alina S. Gerrie, Catherine Burton, Mark Bower, John Kuruvilla, Silvia Montoto, Pam McKay, Christopher P. Fox, Samuel Milliken, Awachana Jiamsakul, Wendy Osborne, Graham P. Collins, Kate Manos, Kim M. Linton, Sunil Iyengar, Shireen Kassam, Michelle Poon Limei, David Kliman, Nicole Wong Doo, Anne-Marie Watson, Pasquale Fedele, Costas K. Yannakou, Stewart Hunt, Matthew Ku, Laurie H. Sehn, Alexandra Smith, Hanna Renshaw, Alice Maxwell, Qin Liu, Rageshri Dhairyawan, Graeme Ferguson, Keir Pickard, Daniel Painter, Nisha Thakrar, Kevin W. Song, Nada Hamad
Journal: Blood
Blood (2024) 143 (2): 152–165.
https://doi.org/10.1182/blood.2023021348
Published: 2024
Includes: Supplemental data
Journal Articles

Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

Marie José Kersten, Martin Dreyling, Kim M. Linton, Dana Chitu, Sanne Tonino, Marcel Kap, Roberto D Liu, Martine E.D. Chamuleau, Hein P.J. Visser, Eva De Jongh, Erik WAF Marijt, Maria B.L. Leijs, Yavuz M. Bilgin, Jan Dürig, Pamela McKay, Tjeerd J.F. Snijders, Andrew Pettitt, Monique C. Minnema, Gabriele Prange-Krex, Maria Cuijpers, Lara H. Böhmer, Lidwine W. Tick, Axel Florschütz, Matthijs Silbermann, Rob Fijnheer, Aart Beeker, Nelleke Tolboom, Cristina Mitea, Anne IJ Arens, Gerben JC Zwezerijnen, Wolfram Klapper, Sarah E. Coupland, Daphne de Jong, Jeanette K. Doorduijn, Josée M. Zijlstra
Journal: Blood
Blood (2022) 140 (Supplement 1): 2283–2285.
https://doi.org/10.1182/blood-2022-156085
Published: 2022
Journal Articles

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

Andrew D. Zelenetz, Wojciech Jurczak, Vincent Ribrag, Kim M. Linton, Graham P. Collins, Mark Bishton, Javier López Jiménez, Bhagirathbhai Dholaria, Andrea Mengarelli, Tycel J. Phillips, Nagendra Prasad Sungala, Henry Chan, Gerardo Musuraca, Oonagh Sheehy, Junyi Yan, Weiming Xu, Michel Azoulay, Pier Luigi Zinzani
Journal: Blood
Blood (2022) 140 (Supplement 1): 3595–3597.
https://doi.org/10.1182/blood-2022-165409
Published: 2022
Journal Articles

A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Kim M. Linton, Adam Vilmar, Mats Jerkeman, Jenny MH Chen, Anke Ohler, Stephan Stilgenbauer, Catherine Thieblemont, Jonathan Lambert, Vittorio Ruggero Zilioli, Juan-Manuel Sancho, Ana Jimenez-Ubieto, Luca Fischer, Toby A. Eyre, Sam Keeping, Julie E Park, James J Wu, Rubina Siddiqi, John Reitan, Gab Castaigne, Gilles Salles
Journal: Blood
Blood (2022) 140 (Supplement 1): 10296–10299.
https://doi.org/10.1182/blood-2022-162638
Published: 2022
Journal Articles

Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Anna Santarsieri, Emily Mitchell, Katherine Sturgess, Pauline Brice, Tobias F. Menne, Wendy Osborne, Thomas Creasey, Kirit M. Ardeshna, Sarah Behan, Kaljit Bhuller, Stephen Booth, Nikesh D. Chavda, Graham P. Collins, Dominic J. Culligan, Kate Cwynarski, Andrew Davies, Abigail Downing, David Dutton, Michelle Furtado, Eve Gallop-Evans, Andrew Hodson, David Hopkins, Hannah Hsu, Sunil Iyengar, Stephen G. Jones, Kim M. Linton, Oliver C. Lomas, Nicolas Martinez-Calle, Abhinav Mathur, Pamela McKay, Sateesh K. Nagumantry, Deirdre O'Mahony, Elizabeth H. Phillips, Neil Phillips, John F. Rudge, Nimish K. Shah, Gwyneth Stafford, Alex Sternberg, Rachel Trickey, Benjamin J. Uttenthal, Natasha Wetherall, Andrew K. McMillan, Michael Stratton, Elisa Laurenti, Peter J. Campbell, George A. Follows
Journal: Blood
Blood (2022) 140 (Supplement 1): 1761–1764.
https://doi.org/10.1182/blood-2022-166543
Published: 2022
Journal Articles

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim M. Linton, Pamela McKay, Henry Chan, Jie Jin, Mingyuan Sun, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Peter J. Browett, Xiaoyan Ke, Craig A. Portell, Catherine Thieblemont, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza Hawkes, Shir-Jing Ho, Keshu Zhou, Zhiyu Liang, Jianfeng Xu, Chris Tankersley, Richard Delarue, Melannie Co, Judith Trotman
Journal: Blood
Blood (2022) 140 (Supplement 1): 573–576.
https://doi.org/10.1182/blood-2022-163371
Published: 2022
Journal Articles

Subcutaneous Epcoritamab in Combination with R 2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial

Kim M Linton, Björn Wahlin, Sirpa Leepä, Franck Morschhauser, Brian Elliot, Tracy Liu, Mariana Cota Stirner, Aqeel Abbas, Lorenzo Falchi
Journal: Blood
Blood (2021) 138 (Supplement 1): 3535.
https://doi.org/10.1182/blood-2021-146629
Published: 2021
Journal Articles

Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

Martin Hutchings, MD PhD, Rogier Mous, MD PhD, Michael Roost Clausen, MD PhD, Peter Johnson, MD FRCP, Kim M Linton, MBChB, PhD, Martine E.D. Chamuleau, MD PhD, David John Lewis, MD, Anna Sureda Balari, MD PhD, David Cunningham, MD FRCP, FMedSci, Roberto S Oliveri, MD PhD, Dena DeMarco, Brian Elliott, MD, Kuo-mei Chen, PhD, Pieternella J. Lugtenburg, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-133820
Published: 2020
Journal Articles

Enhanced Outcome Prediction in Early Stage Classical Hodgkin Lymphoma Using Pre-Treatment Biomarkers and Interim PET (BioPET); A Sub-Analysis of the UK NCRI RAPID Trial

Kim M Linton, MBChB, PhD, Joanna M Oladipo, PhD, Nicholas Counsell, MSc, Janet Taylor, PhD, Cathy Burton, MBBChir, MA, MD FRCPath, Rachel Oakley, PhD, Joanna Williams, PhD, Sally F Barrington, Prof, MD PhD, Richard Byers, BSc, MSc, MBChB, PhD FRCPath, Timothy Illidge, MDPhD, John A. Radford, MD FMedSci
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-136318
Published: 2020
Journal Articles

A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL

Myron S. Czuczman, MD, Andrew Davies, BM PhD, Kim M Linton, MBChB, MRCP, PhD, Nina Wagner-Johnston, Randy D. Gascoyne, MD, David A. Eberhard, MD PhD, Gilles Salles, MDPhD, Thomas E. Witzig, MD, Pier Luigi Zinzani, MD, PhD, George W. Wright, PhD, Louis M. Staudt, MD PhD, Jacqueline Repici, Dale Song, Oliver Manzke, MD, Ian D Lewis, MBBS, PhD
Journal: Blood
Blood (2014) 124 (21): 628.
https://doi.org/10.1182/blood.V124.21.628.628
Published: 2014
Journal Articles

A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Graham P Collins, MA, PhD, Eyre A Toby, MBChB, Chris S. Hatton, MD, John Radford, Kim M Linton, MBChB, MRCP, PhD
Journal: Blood
Blood (2014) 124 (21): 4481.
https://doi.org/10.1182/blood.V124.21.4481.4481
Published: 2014